How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
George W. Bickerstaff, III, insider at CareDx

George W. Bickerstaff, III Insider Information

Director of CareDx
George W. Bickerstaff, III has served as a member of our board of directors since April 2014. Mr. Bickerstaff is currently the managing director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to that Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including chief financial officer of Novartis Pharma AG from October 2000 to May 2005. Previously, George held senior finance and operating roles with various global companies including, IMS, Dun & Bradstreet and General Electric. Mr. Bickerstasff received a BS in engineering and a BA in business administration from Rutgers University in 1978.

What is George W. Bickerstaff, III's net worth?

The estimated net worth of George W. Bickerstaff, III is at least $2.96 million as of May 24th, 2021. Bickerstaff, III owns 114,560 shares of CareDx stock worth more than $2,962,522 as of May 22nd. This net worth evaluation does not reflect any other investments that Bickerstaff, III may own. Learn More about George W. Bickerstaff, III's net worth.

How do I contact George W. Bickerstaff, III?

The corporate mailing address for Bickerstaff, III and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected] Learn More on George W. Bickerstaff, III's contact information.

Has George W. Bickerstaff, III been buying or selling shares of CareDx?

George W. Bickerstaff, III has not been actively trading shares of CareDx during the past quarter. As far as recent transactions, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on George W. Bickerstaff, III's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 39 times. They sold a total of 350,011 shares worth more than $18,189,360.58. The most recent insider tranaction occured on May, 11th when Director Grace Colon sold 5,179 shares worth more than $119,168.79. Insiders at CareDx own 4.6 % of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 5/11/2022.

George W. Bickerstaff, III Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2022Sell25,000$39.11$977,750.00View SEC Filing Icon  
5/21/2021Sell10,000$75.34$753,400.0061,737View SEC Filing Icon  
5/12/2021Sell10,000$63.07$630,700.0071,538View SEC Filing Icon  
See Full Table

George W. Bickerstaff, III Buying and Selling Activity at CareDx

This chart shows George Bickerstaff's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $25.86
Low: $24.25
High: $26.26

50 Day Range

MA: $33.07
Low: $21.70
High: $40.92

2 Week Range

Now: $25.86
Low: $21.25
High: $96.88

Volume

487,305 shs

Average Volume

939,791 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.